<DOC>
	<DOCNO>NCT00727272</DOCNO>
	<brief_summary>The purpose study evaluate compare relative bioavailability Quinine Sulfate 324 mg capsule , manufacture Mutual Pharmaceutical Company , Quinine Sulphate 300 mg tablet , manufactured Government Pharmaceutical Organization , Bangkok Metropolis , Thailand , single oral dose administration fast condition . An additional purpose study evaluate effect food Mutual Pharmaceutical Company product .</brief_summary>
	<brief_title>A Relative Bioavailability Study Quinine Sulfate Capsules Under Fasting Fed Conditions</brief_title>
	<detailed_description>The purpose study evaluate compare relative bioavailability Quinine Sulfate 324 mg capsule , manufacture Mutual Pharmaceutical Company , Quinine Sulphate 300 mg tablet , manufactured Government Pharmaceutical Organization , Bangkok Metropolis , Thailand , single oral dose administration fast condition . An additional purpose study evaluate effect food Mutual Pharmaceutical Company product . Twenty-seven healthy , non-smoking , non-obese , male female volunteer least 18 year age randomly assign crossover fashion receive three dose regimen sequence 7 day washout period dose period . In three dose period , fast least 10 hour , subject receive one dose one three test product ( treatment A - quinine sulfate capsule 324 mg , treatment B - quinine sulphate tablet 300 mg , treatment C - quinine sulfate capsule 324 mg administer thirty minute initiation standardize , high-fat breakfast ) . Subjects fast 4 hour dose . Blood sample draw participant dose 48 hour post-dose time sufficient adequately define pharmacokinetics quinine sulfate feed fasting condition quinine sulphate fasting condition . Sitting blood pressure heart rate obtain prior dose 1 , 2 , 4 12 hour post-dose upon completion study . An electrocardiogram record check-in 2 , 4 , 6 , 12 , 24 hour post-dose . Subjects monitor throughout participation study adverse reaction .</detailed_description>
	<mesh_term>Quinine</mesh_term>
	<criteria>Screening Demographics : All volunteer select study healthy men woman least 18 year age , inclusive , time dosing . The weight range exceed Â± 20 % height body frame per Desirable Weights Adults 1983 Metropolitan Height Weight Table Screening procedure : Each volunteer complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory procedure include : HEMATOLOGY : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count CLINICAL CHEMISTRY : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase HIV antibody hepatitis B surface antigen screen URINALYSIS : dipstick ; full microscopic examination dipstick positive ; URINE DRUG SCREEN : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates phencyclidine SERUM PREGNANCY SCREEN ( female volunteer ) If female : childbearing potential , practice acceptable method birth control duration study judge investigator ( ) , condom spermicide , diaphragm , intrauterine device ( IUD ) , abstinence ; postmenopausal least 2 year ; surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) Volunteers recent history drug alcohol addiction abuse Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant Volunteers demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen Volunteers demonstrate positive drug screen screen study Female volunteer demonstrate positive pregnancy screen Female volunteer currently breastfeed Volunteers history allergic response ( ) quinine relate drug Volunteers history clinically significant allergy include drug allergy Volunteers history clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) Volunteers currently use tobacco product Volunteers take drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose Volunteers report donate great 150mL blood within 28 day prior Period I dose . All subject advise donate blood four week complete study Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study Volunteers report receive investigational drug within 28 day prior Period I dose Volunteers report take systemic prescription medication 14 day prior Period I dose Volunteers QTc &gt; 480 msec screen electrocardiogram ( ECG ) clinically significant finding Volunteers glucose6phosphate dehydrogenese deficiency ( G6PD )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Bioavailability</keyword>
</DOC>